Good
Partially Aligned
Patient Risk:
Low
Summary
Most component/ingredient and general safety side-effect claims are consistent with the provided label excerpts (e.g., epistaxis, nasal discomfort not directly supported, headache/sense of taste not supported, indication wording is close but label specifies seasonal allergic rhinitis and age ≥12).
Category Scores
Accurate Statements
Ryaltris is a prescription nasal spray indicated for the treatment of nasal allergy symptoms.
Indications (1): "RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older."
Ryaltris contains olopatadine as an active ingredient.
Drug/Active ingredients: "Active ingredients: olopatadine hydrochloride and mometasone furoate monohydrate."
Ryaltris contains mometasone furoate as an active ingredient.
Drug/Active ingredients: "Active ingredients: olopatadine hydrochloride and mometasone furoate monohydrate."
Olopatadine is an antihistamine.
Clinical Pharmacology (12.1): "Olopatadine is a histamine-1 (H1) receptor inhibitor."
Mometasone furoate is a corticosteroid.
Clinical Pharmacology (12.1): "Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity."
Common side effects of Ryaltris include nosebleeds.
Warnings/Precautions (5.1): "Epistaxis was observed in 1% of patients treated with RYALTRIS and 0.6% of patients who received placebo..."
Unsupported Statements
Common side effects of Ryaltris include nasal discomfort.
The provided excerpts do not list nasal discomfort as an adverse reaction or frequency for RYALTRIS.
Common side effects of Ryaltris include headache.
The provided excerpts do not list headache as an adverse reaction or frequency for RYALTRIS.
Common side effects of Ryaltris include altered sense of taste.
The provided excerpts do not list altered sense of taste as an adverse reaction or frequency for RYALTRIS.
Contradictions
Important Omissions
Indication age limitation: label specifies "adult and pediatric patients 12 years of age and older"; the AI statement omitted the age qualifier and used broader wording "nasal allergy symptoms."
Importance:
Moderate
Dosage and administration details (e.g., "For nasal use only" and "2 sprays... in each nostril twice daily") were not provided by the AI statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Ingredient/mechanism statements and epistaxis support are on-label. However, several claimed 'common' side effects (nasal discomfort, headache, altered sense of taste) are not supported by the provided label excerpts, and the age restriction was omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several adverse-effect claims are not supported by the provided label excerpts, and the indication age restriction is omitted.
Suggested Improvement
Limit adverse reaction statements to those supported in the provided excerpts (e.g., epistaxis; somnolence is specifically mentioned as <1%). Rephrase the indication to match label wording including "seasonal allergic rhinitis" and "12 years of age and older".